Диссертация (1174208), страница 46
Текст из файла (страница 46)
Franzen, U. L. Mathiesen // Hepatology. – 2006. –V. 44. – P. 865–873.163. Fargion, S. Nonalcoholic fatty liver disease and vascular disease: state-ofthe-art / S. Fargion, M. Porzio, A. L. Fracanzani // World J. Gastroenterol. – 2014.– V. 20 (37). – P. 13306–24.164. Fotbolcu, H. Nonalcoholic fatty liver disease as a multi-systemic disease./H. Fotbolcu, E. Zorlu // World Jю Gastroenterol. – 2016. – V. 22 (16).
– P. 407990.165. Frerichs, F. T. Uber den Diabetes / F. T. Frerichs // Berlin. 1884166. Ganau, A. Patterns of left ventricular hypertrophy and geometric remodelingin essential hypertension / A. Ganau, R. B. Devereux, M. J. Roman // J. Am. Coll.Cardiol. – 1992. – № 19 (1). – Р. 1550–1558.167. Grandone, A. TM6SF2 Glu167Lys polymorphism is associated with lowlevels of LDL-cholesterol and increased liver injury in obese children /A. Grandone, D.
Cozzolino, P. Marzuillo, G. Cirillo, A. di Sessa, L. Ruggiero,M. R. di Palma, L. Perrone, E. Miraglia del Giudice // Pediatr. Obes. – 2016. – V.11. – P. 115–119.168. Jager, J. Liver innate immune cells and insulin resistance: The multiplefacets of Kupffer cells / J. Jager, M. Aparicio-Vergara, M. Aouadi // J. Intern.Med. – 2016. – V. 280. – P. 209–220.169. Janczyk, W. Omega-3 Fatty acids therapy in children with nonalcoholicFatty liver disease: a randomized controlled trial / W. Janczyk, D.
Lebensztejn,298A. Wierzbicka-Rucinska, A. Mazur, J. Neuhoff-Murawska, P. Matusik // Journal ofPediatrics. – 2015. – V. 166 (6). – P. 1358–1363.170.Jelenik, T. Mechanisms of insulin resistance in primary and secondary non-alcoholic fatty liver. / T. Jelenik, K. Kaul, G. Séquaris, U. Flögel, E. Phielix,J. Kotzka, B.
Knebel // Diabetes. – 2017. – V. 66. – P. 2241–2253.171. Jenks, S. J. Hepatic steatosis and non-alcoholic fatty liver disease are notassociated with decline in renal function in people with Type 2 diabetes /S. J. Jenks,B. R. Conway,T. J. Hor,R. M. Williamson,S. Mclachlan,C. Robertson // Diabetic Medicine. – 2014. – V. 31 (9). – P. 1039–1046.172. Johnson, N. A. Aerobic exercise training reduces hepatic and visceral lipidsin obese individuals without weight loss / N. A. Johnson, T.
Sachinwalla,D. W. Walton // Hepatology. – 2009. – V. 50. – P. 1105–1112.173. Hagström, H. Risk for development of severe liver disease in lean patientswith nonalcoholic fatty liver disease: A long-term follow-up study / H. Hagström,P. Nasr, M. Ekstedt, U. Hammar, P. Stal, R. Hultcrantz // Hepatol. Commun. –2018.
– V. 2 (1). – P. 48–57.174. Hayashi, T. Noninvasive Assessment of Advanced Fibrosis Based onHepatic Volume in Patients with Nonalcoholic Fatty Liver Disease / T. Hayashi,S. Saitoh, K. Fukuzawa, Y. Tsuji, J. Takahashi, Y. Kawamura, N.
Akuta // GutLiver. – 2017. – V. 11 (5). – P. 674–683.175. Hossain, N. Comprehensive Updated Review of Pharmaceutical andNonpharmaceuticalTreatmentfor NAFLD/N. Hossain, P. Kanwar, S. R.Mohanty // Gastroenterology research and practice. – 2016; 2016: 7109270.176. Icura, Y. Transitions of histopathologic criteria for diagnosis of nonalcoholicfatty liver disease during the last three decades / Y. Icura // Wld.
J. Hepatol. –2014. – Vol. 12. – №6. – P. 894–900.177. Katsiki, N. Is Nonalcoholic Fatty Liver Disease Indeed the HepaticManifestationofMetabolicSyndrome?/N. Katsiki,P. Perez-Martinez,P. Anagnostis, D. P. Mikhailidis, A. Karagiannis // Curr. Vasc. Pharmacol. – 2018.– V. 16(3). – P. 219–227.299178. Keating, S. E.
Exercise and non-alcoholic fatty liver disease: a systematicreview and meta-analysis / S. E. Keating, D. A. Hackett, J. George, N. A. Johnson// J. Hepatol. – 2012. – V. 57. – P.157–166.179. Kleiner, D. E. Nonalcoholic fatty liver disease: pathologic patterns andbiopsy evaluation in clinical research / D.
E. Kleiner, E. M. Brunt // Semin. LiverDis. – 2012. – V. 32 (1). – P. 3–13.180. Kim, B. J. The association between nonalcoholic fatty liver disease,metabolic syndrome and arterial stiffness in nondiabetic, nonhypertensiveindividuals. / B. J. Kim, N. H. Kim, B. S. Kim, J. H. Kang // Cardiology. – 2012. –V.123. – P. 54–61.181.
Kim, D.Nonalcoholic Fatty Liver Disease and Metabolic Syndrome /D. Kim, A. Touros, W. R. Kim // Clinю Liver Dis. – 2018. – V. 22 (1). – P. 133–140.182. Kim, N.H. Clinical and metabolic factors associated with development andregression of nonalcoholic fatty liver disease in nonobese subjects /N. H.
Kim, J. H. Kim, Y. J. Kim, H. J. Yoo, H. Y. Kim, J. A. Seo // LiverInternational. – 2014. – V. 34 (4). – P. 604–611.183. Kim, N. H. Non-alcoholic fatty liver disease, metabolic syndrome andsubclinical cardiovascular changes in the general population. / N. H. Kim, J. Park,S. H. Kim // Heart. – 2014. – V. 100. – P.
938–43.184. Koplay, M. Importance of imaging and recent developments in diagnosis ofnonalcoholic fatty liver disease / M. Koplay, M. Sivri, H. Erdogan, A. Nayman //World J Hepatol. – 2015. – V. 7 (5). – Р. 769–776.185. Kwok, R. Systematic review with meta-analysis: non-invasive assessment ofnon-alcoholic fatty liver disease–the role of transient elastography and plasmacytokeratin-18 fragments / R.
Kwok, Y. K. Tse, G. L. Wong, Y. Ha, A. U. Lee,M. C. Ngu, H. L. Chan, V. W. Wong // Aliment. Pharmacol. Ther. – 2014. – V. 39.– P. 254–269.186. La Bresque, D.K. World Gastroenterology Organisation Global Guidelines.Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis / D.K. La300Bresque, Z. Abbaz, F. Anania, P. Faenchi // J. Clin. Gastroenterol. – 2014.
– V. 48(6). – Р. 467–473.187. La Brecque, D. R. World Gastroenterology Organisation Global Guidelines:NonalcoholicFattyLiverDiseaseandNonalcoholicsteatohepatitis/D. R. LaBrecque, Z. Abbas, F. Anania // J. Clin. Gastroenterol. – 2014. – V.48, №6. – P. 467–473.188. Lazebnik, L. B. Nonalcoholic fatty liver disease: clinical features, diagnosis,treatment. Recommendations for physicians. Approved by the Congress of theScientificSocietyofGastroenterologistsV. G. Radchenko,E. V. Golovanova,P. V.
Seliverstov,S. I. Sitkin//ofRussia/L. A. Zvenigorodskaya,Eksperimental’nayaiL. B. Lazebnik,Yu. V. Konev,KlinicheskayaGastroenterologiya. – 2017. – V. 138 (2). – P. 22–37.189. Lazo, M. Prevalence of nonalcoholic fatty liver disease in the United States:the Third National Health and Nutrition Examination Survey / M. Lazo, R.Hernaez, M. S.
Eberhardt // Am. J Epidemiol. – 2013. – №178. – Р. 38–43.190. Lee, D. S.Gammaglutamyl-transferaseandmetabolicsyndrome,cardiovascular disease, and mortality risk: the Framingham Heart Study / D. S.Lee, J. C. Evans, S. J. Robins // Arterioscler. Thromb. Vasc. Biol. – 2007.
– V. 27.– P. 127–133.191. Lee, T. H. Prediction of advanced fibrosis in nonalcoholic fatty liver disease:An enhanced model of BARD score / T. H. Lee, S. H. Han, J. D. Yang, D. Kim,M. Ahmed // Gut and Liver. – 2013. – V. 7 (3). – P. 323–328.192. Lee, Y. J. The relationship between arterial stiffness and nonalcoholic fattyliver disease / Y. J. Lee, J. Y. Shim, B. S. Moon // Dig.
Dis. Sci. – 2012. – V. 57. –P. 196–203.193. Leite, N. C. Prevalence and associated factors of nonalcoholic fatty liverdisease in patients with type-2 diabetes mellitus / N. C. Leite, G. F. Salles,A. Araujo // Liver Int. – 2009. – V 29. – Р. 113–119.194. Lonardo, A. Cardiovascular and systemic risk in nonalcoholic fatty liverdisease – atherosclerosis as a major player in the natural course of NAFLD/301A. Lonardo, S. Sookoian, M.
Chonchol, P. Loria, G. Targher // Curr. Pharm. Des. –2013. – V.19 (29). – Р. 5177–5192.195. Lonardo, A. Nonalcoholic fatty liver disease: Evolving paradigms /A. Lonardo,F. Nascimbeni,M. Maurantonio,A. Marrazzo,L. Rinaldi,L. E. Adinolfi // World J. Gastroenterol. – 2017. – V. 23 (36). – P. 6571–6592.196. Loomba, R. The global NAFLD epidemic / R. Loomba, A. J. Sanyal / Nat.Rev. Gastroenterol. Hepatol. – 2013. – №10. – P. 686–690.197.
López-Suárez, A. Nonalcoholic fatty liver disease is associated with bloodpressure in hypertensive and nonhypertensive individuals from the generalpopulation with normal levels of alanine aminotransferase / А. López-Suárez,J. M. R. Guerrero, J. Elvira-González, M. Beltrán-Robles, F. Cañas-Hormigo,A. Bascuñana-Quirell // European Journal of Gastroenterology and Hepatology.
–2011. – V. 23 (11). – P. 1011–1017.198. Ludwig, J. Nonalcoholiс steatohepatitis: Mayo Clinic experiences with ahitherto unnamed disease / J. Ludwig, T. R. Viggiano, D. B. McGill, B. J. Oh //Mayo Clin. Proc. – 1980. – V. 55. – P. 434–438.199.Luukkonen, P. K. Hepatic ceramides dissociate steatosis and insulinresistance in patients with non-alcoholic fatty liver disease / P.
K. Luukkonen,Y. Zhou, S. Sädevirta, M. Leivonen, J. Arola, M. Orešič, T. Hyötyläinen, H. YkiJärvinen // J. Hepatol. – 2016. – V. 64. – P.1167–1175.200. Ma, J. Bi‐directional analysis between fatty liver and cardiovascular diseaserisk factors / J. Ma, S. J. Hwang, A. Pedley, J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
